Search results
Novartis to buy radiology drug specialist Mariana for $1 billion
Reuters via AOL· 4 days agoNovartis agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront,...
2 Magnificent Dividend Stocks to Hold for the Next Decade
Motley Fool via Yahoo Finance· 9 hours agoThe obvious corollary is, not every dividend payer on the market is worth investing in. But let's...
Novartis further entrenches into radiopharma with $1B Mariana buy
FierceBiotech· 4 days agoWith much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep...
Questor: this medical stock is expensive – but worth paying for
The Telegraph via Yahoo Finance· 9 hours agoIt’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value....
Novartis to Buy Mariana Oncology, Paying $1 Billion Upfront
Bloomberg· 4 days agoNovartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can...
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Market Watch· 4 days agoPharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech...
Mather Group LLC. Acquires 1,712 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 4 days agoMather Group LLC. boosted its holdings in Novartis AG (NYSE:NVS – Free Report) by 22.1% in the fourth quarter, according to its most recent 13F filing with the Securities ...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 5 days agoNovartis AG (NYSE:NVS) is one of the largest pharmaceutical companies in the world, many of whose drugs are "gold standards" in the treatment of cancer,...
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
BioPharma Dive via Yahoo Finance· 4 days agoDive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it...
Why selling to Novartis made sense for Mariana
BioPharma Dive via Yahoo Finance· 3 days agoRead in an interview. “The business development deals in the run-up to J.P. Morgan had really conditioned the marketplace.” One of those conversations...
